- Home
- POAI vs IMRN Comparison
POAI vs IMRN Comparison
Compare POAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- IMRN
- Stock Information
- Founded
- POAI 2002
- IMRN 1994
- Country
- POAI United States
- IMRN Australia
- Employees
- POAI N/A
- IMRN N/A
- Industry
- POAI Industrial Specialties
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- POAI Health Care
- IMRN Health Care
- Exchange
- POAI Nasdaq
- IMRN Nasdaq
- Market Cap
- POAI 8.9M
- IMRN 10.1M
- IPO Year
- POAI N/A
- IMRN N/A
- Fundamental
- Price
- POAI $1.06
- IMRN $1.79
- Analyst Decision
- POAI Hold
- IMRN Strong Buy
- Analyst Count
- POAI 1
- IMRN 1
- Target Price
- POAI N/A
- IMRN $5.00
- AVG Volume (30 Days)
- POAI 313.3K
- IMRN 23.1K
- Earning Date
- POAI 05-13-2025
- IMRN 05-06-2025
- Dividend Yield
- POAI N/A
- IMRN N/A
- EPS Growth
- POAI N/A
- IMRN N/A
- EPS
- POAI N/A
- IMRN N/A
- Revenue
- POAI $1,623,817.00
- IMRN $4,048,286.00
- Revenue This Year
- POAI $486.27
- IMRN N/A
- Revenue Next Year
- POAI $65.50
- IMRN N/A
- P/E Ratio
- POAI N/A
- IMRN N/A
- Revenue Growth
- POAI N/A
- IMRN 82.90
- 52 Week Low
- POAI $0.55
- IMRN $1.60
- 52 Week High
- POAI $3.06
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- POAI 47.00
- IMRN 51.61
- Support Level
- POAI $0.85
- IMRN $1.70
- Resistance Level
- POAI $1.44
- IMRN $1.91
- Average True Range (ATR)
- POAI 0.11
- IMRN 0.17
- MACD
- POAI 0.00
- IMRN 0.01
- Stochastic Oscillator
- POAI 42.86
- IMRN 50.71
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.